Inhibikase Therapeutics Inc. (IKT)
NASDAQ · Healthcare
Inhibikase Therapeutics Inc. Long Term Debt 2020–2024
Inhibikase Therapeutics Inc. annual/quarterly long term debt history from 2021 to 2023. Long term debt refers to financial obligations that are due more than one year in the future.
- Inhibikase Therapeutics Inc. long term debt for the quarter ending December 31, 2023 were 381,784, a 53.38% increase year-over-year.
- Inhibikase Therapeutics Inc. long term debt for 2023 were 381,784, a 53.38% increase from 2021.
- Inhibikase Therapeutics Inc. long term debt for 2021 were 248,911.
Long Term Debt
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Inhibikase Therapeutics Inc. Annual Long Term Debt (Millions of US $) | |
|---|---|
| 2023 | $0 |
| 2021 | $0 |
| Inhibikase Therapeutics Inc. Quarterly Long Term Debt (Millions of US $) | |
|---|---|
| 2023-12-31 | $0 |
| 2021-12-31 | $0 |
Inhibikase Therapeutics Inc. Long Term Debt — FAQ
Inhibikase Therapeutics Inc. (IKT) long term debt over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see IKT's long term debt history?
The chart and table above show Inhibikase Therapeutics Inc.'s long term debt by year and by quarter, including the growth rate.